Molecular Regulation of Bone Remodeling in Osteoporosis and Current Therapeutic Approaches
Abstract
Osteoporosis arises from an imbalance in bone remodeling in which osteoclast resorption surpasses osteoblast activity. This process is regulated by the receptor activator of NF-κB ligand/receptor activator of NF-κB/osteoprotegerin system and Wnt/β-catenin signaling pathway, which are influenced by hormones, cytokines, and lifestyle factors. This condition adversely affects the quality of life by causing pain, restricted mobility, and increased mortality. Bone mineral density testing, including a fracture risk assessment tool, is part of the diagnostic process, along with laboratory tests to exclude secondary causes. Management strategies include lifestyle modifications, calcium and vitamin D supplementation, and pharmacological interventions, such as bisphosphonates, denosumab, and parathyroid hormone analogs. Moreover, nanoengineered biomaterials and scaffolds have emerged as promising approaches for hastening bone regeneration, specifically in osteoporotic fractures, by enhancing osteointegration, angiogenesis, and the meticulous release of osteoinductive chemicals. Promising treatments, such as sclerostin inhibitors, nanocarrier-based drug delivery systems, and natural antioxidants, control bone metabolism by attenuating oxidative stress and inflammation, thereby providing novel opportunities for disease management. This review provides a comprehensive and integrated perspective on the molecular regulation of bone remodeling by linking the RANK/RANKL/OPG axis,…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.